Stockscreener 앱 받기
27.46
3.70%
0.98
시간 외 거래:
27.46
전일 마감가:
$26.48
열려 있는:
$26.46
하루 거래량:
327.51K
Relative Volume:
0.91
시가총액:
$1.31B
수익:
-
순이익/손실:
$-111.48M
주가수익비율:
-9.5846
EPS:
-2.865
순현금흐름:
$-88.09M
1주 성능:
-4.22%
1개월 성능:
-8.44%
6개월 성능:
+4.17%
1년 성능:
+180.78%
1일 변동 폭
$26.01
$27.95
1주일 범위
$26.01
$29.84
52주 변동 폭
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
명칭
Rapport Therapeutics Inc
전화
857-321-8020
주소
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
27.46 | 1.26B | 0 | -111.48M | -88.09M | -2.865 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 개시 | Wells Fargo | Overweight |
| 2025-11-19 | 개시 | BTIG Research | Buy |
| 2025-09-16 | 개시 | Truist | Buy |
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-04-08 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 개시 | Jefferies | Buy |
| 2024-07-02 | 개시 | Stifel | Buy |
| 2024-07-02 | 개시 | TD Cowen | Buy |
모두보기
Rapport Therapeutics Inc 주식(RAPP)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Aug Selloffs: Why is Rapport Therapeutics Inc stock going up2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Buyout Rumor: Does Rapport Therapeutics Inc have strong fundamentals2026 Highlights & Long-Term Capital Growth Strategies - baoquankhu1.vn
Sell Signal: Will Rapport Therapeutics Inc benefit from AI trends2026 Drop Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
What hedge funds are buying Rapport Therapeutics Inc2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Update Recap: Why is Rapport Therapeutics Inc stock going up2026 Volume Leaders & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Whats the outlook for Rapport Therapeutics Incs sectorWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Take Profit: Is Rapport Therapeutics Inc undervalued by DCF analysisWeekly Loss Report & Stock Portfolio Risk Management - baoquankhu1.vn
Truist reiterates Rapport Therapeutics stock rating on phase 3 plans - Investing.com
Baker BROS. Advisors LP Has $45.95 Million Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat
HC Wainwright & Co. Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - MSN
Why Rapport Therapeutics (RAPP) Is Down 7.9% After RAP-219 China Deal And Shelf Filing - simplywall.st
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Q1 EPS Forecast for Rapport Therapeutics Boosted by Analyst - Defense World
Q1 EPS Estimate for Rapport Therapeutics Lifted by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
(RAPP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $50.80 Consensus PT from Brokerages - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.7%Should You Sell? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Equities Analysts Offer Predictions for RAPP FY2030 Earnings - MarketBeat
Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat
Day Trade: Will Rapport Therapeutics Inc stock go up in YEARMarket Weekly Review & Scalable Portfolio Growth Methods - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $46.00 at Wells Fargo & Company - MarketBeat
BTIG raises Rapport Therapeutics stock price target on trial progress By Investing.com - Investing.com Canada
Jones Trading reiterates Rapport Therapeutics stock rating on epilepsy progress - Investing.com Canada
Stifel reiterates Rapport Therapeutics stock rating after results By Investing.com - Investing.com Canada
Rapport Therapeutics Inc (RAPP) Reports a Wider Loss for Q4 2025 - AlphaStreet
Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Rapport Therapeutics Reports Strong 2025 Results, Advances RAP-219 Epilepsy Drug to Phase 3 with $490M Cash Runway - Minichart
Rapport’s RAP-219 gets more phase III funding with Tenacia deal - BioWorld MedTech
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down on Disappointing Earnings - MarketBeat
Rapport Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Rapport Therapeutics: Advancing Precision Neuroscience with RAP Technology Platform for Neurological and Psychiatric Disorders 4048 - Minichart
Rapport Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (RAPP) Rapport Therapeutics Posts Q4 Net Loss $0.72 a Share, vs. FactSet Est of $0.70 Loss - marketscreener.com
Rapport Therapeutics (NASDAQ:RAPP) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
Rapport Therapeutics 2025 10‑K: Net loss $111.5M, EPS $(2.86) - TradingView
Rapport Therapeutics (Nasdaq: RAPP) details 2025 losses and RAP‑219 epilepsy progress - Stock Titan
RAP-219 epilepsy drug cut seizures 77.8% in Phase 2a trial - Stock Titan
Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential By Investing.com - Investing.com Canada
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Maintained Buy: RAPP analyst rating on Rapport Therapeutics, Inc. Common Stock Mar 2026 - Meyka
Top Executive’s Surprise Stock Move Shakes Up Rapport Therapeutics - TipRanks
Cheryl Gault Sells 2,014 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
BTIG reiterates Rapport Therapeutics stock rating citing selectivity By Investing.com - Investing.com Canada
Rapport Therapeutics stock holds Buy at TD Cowen on China deal - Investing.com Canada
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China - Bitget
Rapport Therapeutics and Tenacia Biotechnology Announce - GlobeNewswire
How Rapport Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - Naître et grandir
Published on: 2026-03-07 16:24:29 - baoquankhu1.vn
Rapport Therapeutics Inc (RAPP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):